LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2683 | 3694 | 0.7263 | 0.5440 |
| SK-BR-3 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3725 | 3694 | 1.0085 | 1.0141 |
| SK-BR-3 | QL-X-138 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2124 | 3694 | 0.5752 | 0.2922 |
| SK-BR-3 | QL-XII-47 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1912 | 3694 | 0.5177 | 0.1965 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1766 | 3694 | 0.4783 | 0.1308 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1744 | 3694 | 0.4723 | 0.1208 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 4001 | 3694 | 1.0833 | 1.1387 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3280 | 3694 | 0.8881 | 0.8136 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 4313 | 3694 | 1.1676 | 1.2793 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 4158 | 3694 | 1.1257 | 1.2094 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3713 | 3694 | 1.0053 | 1.0088 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2386 | 3694 | 0.6461 | 0.4104 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3294 | 3694 | 0.8917 | 0.8196 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 4204 | 3694 | 1.1380 | 1.2300 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3803 | 3694 | 1.0295 | 1.0491 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3134 | 3694 | 0.8485 | 0.7477 |
| SK-BR-3 | Torin1 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1536 | 3694 | 0.4160 | 0.0270 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1289 | 3694 | 0.3491 | -0.0844 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1253 | 3694 | 0.3393 | -0.1008 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2777 | 3694 | 0.7519 | 0.5867 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3734 | 3694 | 1.0110 | 1.0183 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3973 | 3694 | 1.0757 | 1.1261 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3448 | 3694 | 0.9335 | 0.8892 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3180 | 3694 | 0.8608 | 0.7682 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1563 | 3694 | 0.4232 | 0.0391 |